UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 898

Sortiert nach

Prediction models of long‐term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles

Hepatology (Baltimore, Md.), 2013-08, Vol.58 (2), p.546-554

2013

Link zum Volltext

Verfügbarkeit prüfen

Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression

Hepatology (Baltimore, Md.), 2016-08, Vol.64 (2), p.381-389

2016

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir

Alimentary pharmacology & therapeutics, 2019-01, Vol.49 (2), p.218-228

2019

Link zum Volltext

Verfügbarkeit prüfen

Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma

Journal of hepatology, 2012-02, Vol.56 (2), p.412-418

2012

Link zum Volltext

Verfügbarkeit prüfen

Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death

Gastroenterology (New York, N.Y. 1943), 2010-05, Vol.138 (5), p.1747-1754.e1

2010

Link zum Volltext

Verfügbarkeit prüfen

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment

PloS one, 2019-10, Vol.14 (10), p.e0222221-e0222221

2019

Link zum Volltext

Verfügbarkeit prüfen

Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B

Alimentary pharmacology & therapeutics, 2023-08, Vol.58 (3), p.334-345

2023

Link zum Volltext

Verfügbarkeit prüfen

Persistently high HBsAg levels during HBeAg‐seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients

Alimentary pharmacology & therapeutics, 2024-04, Vol.59 (8), p.993-1002

2024

Link zum Volltext

Verfügbarkeit prüfen

Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-Up Study

Gastroenterology (New York, N.Y. 1943), 2010-08, Vol.139 (2), p.474-482

2010

Link zum Volltext

Verfügbarkeit prüfen

Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan

Gastroenterology (New York, N.Y. 1943), 2008-07, Vol.135 (1), p.111-121

2008

Link zum Volltext

Verfügbarkeit prüfen

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals

PloS one, 2019-04, Vol.14 (4), p.e0214323-e0214323

2019

Link zum Volltext

Verfügbarkeit prüfen

Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non‐alcoholic fatty liver disease

Liver international, 2023-09, Vol.43 (9), p.1901-1908

2023

Link zum Volltext

Verfügbarkeit prüfen

Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients

The Kaohsiung journal of medical sciences, 2024-06, Vol.40 (6), p.589-598

2024

Link zum Volltext

Verfügbarkeit prüfen

Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer–Specific Mortality in a Large Nationwide Cohort

Hepatology (Baltimore, Md.), 2021-10, Vol.74 (4), p.1994-2006

2021

Link zum Volltext

Verfügbarkeit prüfen

The role of hepatitis B virus core‐related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen‐negative patients

Journal of viral hepatitis, 2021-08, Vol.28 (8), p.1141-1149

2021

Link zum Volltext

Verfügbarkeit prüfen

Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C

Journal of clinical oncology, 2011-09, Vol.29 (27), p.3643-3650

2011

Link zum Volltext

Verfügbarkeit prüfen

Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting

PloS one, 2022-08, Vol.17 (8), p.e0272567-e0272567

2022

Link zum Volltext

Verfügbarkeit prüfen

Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population‐based study

Alimentary pharmacology & therapeutics, 2018-11, Vol.48 (9), p.993-1002

2018

Link zum Volltext

Verfügbarkeit prüfen

Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation

PloS one, 2020-11, Vol.15 (11), p.e0242113-e0242113

2020

Link zum Volltext

Verfügbarkeit prüfen

Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients

The Journal of infectious diseases, 2022-06, Vol.225 (11), p.1974-1981

2022

Link zum Volltext

Verfügbarkeit prüfen

Letter: the association between chronic viral hepatitis and metabolic syndrome – Authors' reply

Alimentary pharmacology & therapeutics, 2019-01, Vol.49 (2), p.233-234

2019

Link zum Volltext

Verfügbarkeit prüfen

Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL

Scientific reports, 2017-05, Vol.7 (1), p.1839-9, Article 1839

2017

Link zum Volltext

Verfügbarkeit prüfen

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

JAMA : the journal of the American Medical Association, 2006-01, Vol.295 (1), p.65

2006

Link zum Volltext

Verfügbarkeit prüfen

Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers

International journal of cancer, 2017-08, Vol.141 (4), p.711-720

2017

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis C viral load, genotype, and increased risk of developing end‐stage renal disease: REVEAL‐HCV study

Hepatology (Baltimore, Md.), 2017-09, Vol.66 (3), p.784-793

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 898

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(826)
Mit Volltextzugriff
(812)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(688)
Life Sciences & Biomedicine
(501)
Humans
(484)
Male
(402)
Female
(389)
Middle Aged
(361)
Adult
(281)
Aged
(241)
Gastroenterology & Hepatology
(208)
Hepatocellular Carcinoma
(165)
Risk Factors
(139)
Biological And Medical Sciences
(134)
Medical Sciences
(125)
Hepatitis
(120)
Science & Technology - Other Topics
(117)
Patients
(115)
Multidisciplinary Sciences
(114)
Hepatitis B Virus
(111)
Retrospective Studies
(107)
Liver Cancer
(104)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Prediction models of long‐term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles

Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression

Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir

Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma

Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment

Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B

Persistently high HBsAg levels during HBeAg‐seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients

Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-Up Study

Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals

Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non‐alcoholic fatty liver disease

Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients

Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer–Specific Mortality in a Large Nationwide Cohort

The role of hepatitis B virus core‐related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen‐negative patients

Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C

Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting

Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population‐based study

Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation

Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients

Letter: the association between chronic viral hepatitis and metabolic syndrome – Authors' reply

Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers

Hepatitis C viral load, genotype, and increased risk of developing end‐stage renal disease: REVEAL‐HCV study

Suchergebnisse filtern